title: Whole-metagenome-sequencing of the fecal microbiota approx. 200 days after interruption of AH1206 consumption - subject F
design: A double-blind, placebo-controlled, human crossover study with 22 healthy human subjects (22 and 38 years of age) was conducted with the primary objectives to determine acceptability and persistence of B. longum subsp. longum AH1206 at a daily dose of 10^10 cells. The study was conducted over two 7-week test periods. Each period included a baseline, a 14-day treatment and a 28-day test of persistence. Fecal samples sequenced were collected at baseline ( pre-AH1206 treatment), last day of AH1206 consumption (14 days) and last day of placebo consumption (14 days). The Nextera DNA Sample Prep Kit (Illumina, San Diego, CA, USA) was used for library preparation.